Technology sublicensees and agreements:

  - Qiagen ( www.qiagen.com )
  - Lonza ( www.lonza.com )
  - Mologen ( www.mologen.com )
  - CellMade ( www.cellmade.com )

Lonza (Cambrex)
Synvolux Therapeutics B.V. announced that it signed an agreement giving Lonza (Cambrex Bio Science) (Walkersville, MD, USA) non-exclusive rights for the distribution of its proprietary materials for the transfection of primary cells. Lonza intends to launch this product under its trademark Primefect in the first quarter of 2007.

Vivomicx
Synvolux is collaborating in the field of targeted siRNA delivery with Vivomicx ( http://www.vivomicx.nl/ ). Vivomicx technology analyses in vivo local knock down of genes that is created by selective delivery of siRNA into target (endothelial) cells, and hence assists in showing proof delivery success. Furthermore, it provides clues for downstream consequences of gene knock out in the complex in vivo environment.

The Jackson Laboratory
The Jackson Laboratory Mouse Repository is breeding our EpCAM transgenic animal which is maded available for the research community ( http://jaxmice.jax.org/strain/008426.html ).

CellMade
Synvolux Therapeutics BV, of Groningen, The Netherlands is CellMade©’s preferred partner for transfection/transduction solutions for primary cell cultures; CellMade© holds a license (for research use only) to Synvolux transfection technologies.

Synvolux is now pursuing the use of its technology in the development of several therapeutic products, both in-house as well as in collaboration with pharma and biotechnology partners. Several feasibility programs with prospective partners, testing the potential of SAINT for the delivery of certain therapeutic macromolecules, are already underway. The company is now actively seeking additional collaborations and will make its technology available to its collaboration partners on a semi-exclusive basis.

We are also interested in co-development partners with relevant expertise in specific disease’s to assist us in developing application in their specific knowledge base. This approach will aim us to broaden our technology further towards a general accepted delivery platform technology.